MCM
LIMNW

Moore Capital Management’s Liminatus Pharma Warrants LIMNW Stock Holding History

Moore Capital Management’s Portfolio LIMNW Stock Details LIMNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Hold
125,000
– – ﹤0.01% 624
2025
Q4 		$4.38K Hold
125,000
– – ﹤0.01% 657
2025
Q3 		$18.5K Hold
125,000
– – ﹤0.01% 589
2025
Q2 		$30.4K Buy
+125,000
New +$24.6K ﹤0.01% 502

Other funds holding LIMNW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Moore Capital Management's LIMNW Position: Q1 2026 in Review

Moore Capital Management held its Liminatus Pharma Warrants (LIMNW) position steady in Q1 2026 at 125,000 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #624.

Moore Capital Management first reported a position in LIMNW in Q2 2025 and has held it in 4 quarters since. The position peaked at $30.4K in Q2 2025. 21 funds tracked by Wall St. Rank hold LIMNW as of Q1 2026.

  • Moore Capital Management held 125,000 shares of Liminatus Pharma Warrants worth $5K as of Q1 2026.
  • Moore Capital Management left its Liminatus Pharma Warrants share count unchanged in Q1 2026.
  • Liminatus Pharma Warrants made up ﹤0.01% of Moore Capital Management's portfolio in Q1 2026, its #624 holding.
  • Moore Capital Management first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 4 quarters since.
  • Moore Capital Management's Liminatus Pharma Warrants position peaked at $30.4K in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.